A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial
| Autor: | Vivek Nair, Nandini Gokulchandran, Mili Shah, Jignasha Captain, Ummeammara Khanbande, Balaji Tuppekar, Pallavi Khubchandani, Alok Sharma, Ritu Varghese, Pooja Kulkarni, Prakash Gote, Sushil Kasekar, Radhika Pradhan, Hemangi Sane, Amruta Paranjape, M.K. Pradeep, Satya Lakshmi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_treatment Immunology Pilot Projects Article 03 medical and health sciences 0302 clinical medicine Ozone medicine Immunology and Allergy Humans Stage (cooking) Antiviral Adverse effect Saline Pharmacology business.industry SARS-CoV-2 Oxygenation Middle Aged Ozone therapy medicine.disease Ozonised saline COVID-19 Drug Treatment Clinical trial Coronavirus Pneumonia 030104 developmental biology Treatment Outcome Chemotherapy Adjuvant 030220 oncology & carcinogenesis Anesthesia Administration Intravenous Female business Covid-19 Corrigendum Adjuvant |
| Zdroj: | International Immunopharmacology |
| ISSN: | 1878-1705 |
| Popis: | Objective Ozone therapy has tremendous therapeutic potential owing to its antiviral, anti-inflammatory and antioxidant properties, and potential to improve oxygenation. A pilot clinical trial was conducted to evaluate the safety and efficacy of intravenous ozonised saline treatment in patients with moderate COVID-19 pneumonia. Patients and Methods 10 patients were administered 200 ml freshly prepared ozonised saline intravenously over 1 h once a day for 8 days along with standard medical treatment. Clinical symptoms were monitored everyday and laboratory biomarkers, radiological findings at 1,3,6,10 days. Telephonic follow up was done for all after discharge till Day 14. 7 out of 10 patients required oxygen supplementation at recruitment. Results There was severe adverse event recorded in the study group. All patients improved from moderate to mild category in average 8 days and were discharged in average 9.7 days. None deteriorated to severe stage. All clinical symptoms resolved within 6 days and oxygen supplementation requirement reduced to none within 4.1 days. There was statistically significant reduction in CRP (p = 0.003), D-Dimer (p = 0.049), IL6 (p = 0.002) and statistically significant improvement (p = 0.001) in SpO2/FiO2 ratio. Change in LDH was borderline statistically not significant (p = 0.058). All patients showed significant resolution of bilateral interstitial infiltrates at the end of 10 days. Conclusion Resolved clinical symptoms, improved oxygenation, clearance of infiltrates on Chest X-ray and improvement in biomarkers in a short period with non-progression of the disease showed that IV ozonised saline therapy was safe and effective to prevent disease progression in COVID-19, making it an effective novel therapeutic tool. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect